Figure 4.

KCC2 activation does not induce gross modifications in mouse behavior but does protect against PTZ-induced seizures

(A) Mice were injected s.c. with 50 mg/kg 350 in 5% BCD. Drug accumulation was then measured over a time course of 8 h via liquid chromatography tandem mass spectrometry (LC-MS/MS) (n = 3–4 mice).

(B) Mice were dosed with 350 50 mg/kg s.c., and 2–3 h later, they were placed in the center of a 60 × 60 cm open field and allowed to explore for 40 min. The total distance traveled and time in the center of the area were then quantified and compared (n = 9 mice).

(C) Mice were injected with 25 mg/kg 350 (i.v.) or V. 1 h later, mice were subjected to continuous video monitoring and injected with increasing amounts of PTZ to a maximum of 200 mg/kg. The doses of PTZ to induce hindlimb clonus were compared (n = 14 mice).

In all panels, p values were determined using t tests, ∗p < 0.05.